Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.

Date publication

mars 2018

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29349829

Résumé

Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head-to-head, superiority and non-inferiority trials in patients with IBD are expected in the future. The clinical relevance of the magnitude of the effect size is often debated.

Mots clés

Adult, Child, Clinical Trials as Topic, psychology, Data Interpretation, Statistical, Female, Humans, Inflammatory Bowel Diseases, therapy, International Agencies, Male, Perception, Physicians, psychology, Practice Patterns, Physicians', statistics & numerical data, Remission Induction, Societies, Medical, Surveys and Questionnaires

Référence

Aliment. Pharmacol. Ther.. 2018 Mar;47(6):773-783